AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 241
- Registration Number
- NCT00878501
- Locations
- 🇸🇰
Research Site, Zilina, Slovakia
Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00878618
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00878930
- Locations
- 🇦🇷
Research Site, Tucuman, Argentina
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 254
- Registration Number
- NCT00877890
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Regional Observation of the Metabolic Syndrome
Completed
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00874952
- Locations
- 🇮🇹
Research Site, Torino, Italy
Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 339
- Registration Number
- NCT00873249
- Locations
- 🇪🇸
Research Site, Zamora, Spain
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide
Completed
- Conditions
- Advanced Prostate Cancer
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 340
- Registration Number
- NCT00871585
- Locations
- 🇭🇷
Research Site, Zagreb, Croatia
AZD5672 Bioavailability Study in Healthy Male and Female Subjects
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00871767
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 255
- Registration Number
- NCT00870194
- Locations
- 🇲🇽
Research Site, Tampico, Mexico
Treatment of Hypertension in Primary Care in Spain
Completed
- Conditions
- Hypertension
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2009-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2160
- Registration Number
- NCT00868881
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain